Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
BioReference Laboratories, a subsidiary of OPKO Health (NASDAQ: OPK), has launched a COVID-19 testing program aimed at U.S. crew and guests cruising with Royal Caribbean Group. This program mandates rapid PCR testing for unvaccinated guests prior to embarkation and at the end of their voyage, with additional testing during the cruise as needed. The initiative is designed to enhance safety for travelers, providing results within 40 minutes of arrival at the port. BioReference, a leading lab in the U.S., serves approximately 19 million patients annually and offers extensive testing solutions.
OPKO Health, Inc. (NASDAQ: OPK) has announced a partnership between its subsidiary EirGen Pharma and Nicoya Macau Limited for the commercialization of RAYALDEE in Greater China. The agreement includes an upfront payment of $5 million and additional payments contingent on development milestones, totaling up to $115 million. Nicoya will handle regulatory approvals and commercialization. With an estimated 19 million patients with stage 3 or 4 chronic kidney disease in the region, this collaboration aims to tap into a significant market opportunity.
OPKO Health, Inc. (NASDAQ: OPK) announced that its subsidiary, EirGen Pharma, has agreed to sell its Waterford, Ireland facility to Horizon Therapeutics for $65 million. This sale will streamline EirGen’s operations, focusing on oral solid dose products. CEO Phillip Frost emphasized the transaction strengthens OPKO's balance sheet while cutting expenses and enhancing efficiency. The deal is expected to close in about a month, pending governmental approvals.
OPKO Health (NASDAQ: OPK) will participate in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Management will engage in a fireside chat on June 2 at 11:30 a.m. Eastern time. The chat will be available via live webcast and archived on OPKO Health’s investor website. Additionally, one-on-one virtual meetings with investors will occur throughout the day. OPKO Health focuses on biopharmaceuticals and diagnostics, aiming to lead in growing markets through innovative technologies.
OPKO Health (NASDAQ: OPK) has transferred the rights to its product RAYALDEE® in Japan from Japan Tobacco (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). The agreement follows JT's decision to terminate its exclusive rights based on a review of its pipeline. EirGen Pharma will now work with VFMCRP under an existing agreement for the product's commercialization in Japan and other markets. RAYALDEE® treats secondary hyperparathyroidism in chronic kidney disease patients and is approved in the U.S. and 11 European countries.
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders to convert $55.42 million of its 4.50% Convertible Senior Notes due 2025 into shares of common stock. The exchange will be based on a volume-weighted average price with a floor price of $3.50 per share, starting today. Additionally, OPKO will pay accrued interest to the noteholders in cash. This move is expected to reduce the outstanding borrowed shares related to a previous share lending agreement with Jefferies Capital Services.
OPKO Health reported a significant increase in revenues for Q1 2021, reaching $545.2 million, compared to $211.5 million in Q1 2020. Net income was $31.1 million, or $0.05 per diluted share, recovering from a net loss of $59.1 million a year prior. COVID-19 testing spurred a 158% rise in test volume at BioReference Laboratories, processing 4.3 million PCR tests and expanding services to schools and sports leagues. However, sales of RAYALDEE decreased significantly, reflecting challenges in the base testing business.
BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has renewed its role as the COVID-19 testing provider for Major League Soccer (MLS) for the second consecutive year. This renewal, effective from April 17, 2021, includes providing laboratory-based PCR and point-of-care COVID-19 testing for players, match officials, and staff across 13 teams. Additionally, testing will extend to fans attending home games, starting with the New England Revolution's match on April 24. BioReference's involvement began during the 2020 MLS is Back Tournament, showcasing its commitment to ensuring safety in sports during the pandemic.
OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q1 2021 on April 28, 2021, after U.S. markets close. The company will host a conference call at 4:30 PM ET to discuss the results and provide financial guidance. Participants can pre-register for the call or access it via webcast. A replay will be available shortly after the call. OPKO is focused on establishing strong positions in large markets through its innovative biopharmaceutical and diagnostics technologies.
On April 1, 2021, BioReference Laboratories, an OPKO Health company (NASDAQ:OPK), announced a COVID-19 testing agreement with Major League Baseball (MLB) for the 2021 season. This partnership involves providing on-site rapid PCR testing for all 30 MLB teams, starting from Opening Day. BioReference, already servicing all five major professional men's sports leagues in the U.S., aims to support a safe and full MLB season. This collaboration signifies BioReference's commitment to health and safety in sports amidst the ongoing pandemic.